Form 4: Corcept Officer Exercises Options, Sells Shares

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc. (CORT), exercised 5,000 stock options at an exercise price of $13.56 per share.
• Concurrently, Lyon sold 5,000 shares of Corcept Therapeutics common stock at a weighted average price of $73.6489 per share, with actual sale prices ranging from $73.47 to $73.945.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Lyon on August 30, 2024.
• Following these transactions, Lyon beneficially owns 10,277 shares of common stock, which includes 1,380 shares underlying unvested restricted stock awards granted on various dates in 2024 and 2025.
• Lyon retains 16,571 stock options with an exercise price of $13.56 and an expiration date of February 7, 2030.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling. The significant gain from option exercise is a positive for the officer.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale not based on immediate, non-public information.
• The sale price of $73.6489 per share is significantly higher than the exercise price of $13.56, indicating a substantial gain for the officer.

Negatives

• An officer selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors, although the pre-arranged nature mitigates concerns about opportunistic selling.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the sale as a routine liquidity event for an executive, especially given the 10b5-1 plan. The transaction itself does not directly impact company operations or strategy.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, maintaining a 'hold' position based solely on this filing.

Keywords

Corcept Therapeutics, CORT, Joseph Douglas Lyon, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Officer Transaction